PROK

ProKidney Corp. NASDAQ Listed Jun 30, 2021

Healthcare ·Biotechnology ·US · prokidney.com

$1.88

Mkt Cap $544.3M

52w Low $0.54 20.3% of range 52w High $7.13

50d MA $2.02 200d MA $2.38

P/E (TTM) -3.7x

EV/EBITDA -3.6x

P/B 0.9x

Debt/Equity 0.0x

ROE 6.8%

P/FCF -2.2x

RSI (14) —

ATR (14) —

Beta 1.86

50d MA $2.02

200d MA $2.38

Avg Volume 874.9K

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

SIC Code

2836

CIK (SEC)

1850270

Phone

336 999 7028

2000 Frontis Plaza Blvd. · Winston-Salem, NC 27103 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 18, 2026	AMC	-0.16	-0.14	+12.5%	2.08	-1.0%	-6.2%	-7.2%	-6.7%	-13.9%	-12.0%	—
Nov 10, 2025	AMC	-0.12	-0.12	+0.0%	2.70	+3.0%	+3.7%	-0.7%	-15.6%	-10.7%	-16.7%	—
Aug 12, 2025	AMC	-0.14	-0.13	+7.1%	2.24	+0.4%	+5.8%	+8.0%	+5.4%	+13.4%	+4.0%	—
May 12, 2025	AMC	-0.16	-0.13	+18.8%	0.75	+1.4%	+15.8%	+2.8%	+13.3%	+7.5%	+7.8%	—
Mar 17, 2025	AMC	-0.14	-0.17	-21.4%	1.04	-1.0%	-6.8%	-4.7%	-9.4%	-7.7%	-1.9%	—
Nov 12, 2024	AMC	-0.14	-0.14	+0.0%	2.05	+3.4%	+1.0%	+4.9%	-17.1%	-19.0%	-12.2%	—
Aug 9, 2024	AMC	-0.17	-0.16	+5.9%	2.18	+5.5%	-4.6%	+4.1%	+4.6%	+9.6%	+10.1%	—
May 10, 2024	AMC	-0.25	-0.16	+36.0%	2.81	+3.2%	+9.6%	+46.6%	+39.5%	+34.9%	+44.5%	—
Mar 21, 2024	AMC	-0.19	-0.09	+52.6%	1.37	+1.5%	+2.2%	+5.1%	+16.1%	+14.6%	+19.7%	—
Nov 14, 2023	AMC	-0.19	-0.18	+5.3%	1.52	-2.0%	-8.6%	-19.1%	-20.4%	+15.8%	+22.4%	—
Aug 10, 2023	AMC	-0.41	-0.14	+65.9%	12.72	+1.9%	+1.7%	-7.5%	-13.4%	-19.0%	-23.2%	—
May 11, 2023	AMC	-0.39	-0.16	+59.0%	9.02	+2.0%	+1.0%	+2.2%	+7.9%	+13.0%	+4.3%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Jul 15	UBS	Maintains	Buy → Buy	—	$3.69	$4.25	+15.2%	-8.7%	+1.1%	-4.6%	-14.6%	-12.7%
Jul 14	Guggenheim	Maintains	Buy → Buy	—	$4.54	$4.78	+5.3%	-18.7%	-25.8%	-17.8%	-22.5%	-30.6%
Jul 9	Citigroup	Maintains	Buy → Buy	—	$3.73	$5.81	+55.8%	+16.4%	+38.9%	+21.7%	-1.1%	-9.7%
Jun 30	BofA Securities	Downgrade	Neutral → Underperform	—	$0.67	$0.64	-3.8%	-11.5%	-15.5%	-13.5%	-4.7%	-9.3%
Sep 4	BofA Securities	Maintains	Neutral → Neutral	—	$2.40	$2.31	-3.8%	-9.2%	-1.2%	-2.9%	-0.4%	+0.4%
Jun 10	Jefferies	Maintains	Buy → Buy	—	$3.19	$3.31	+3.8%	-5.3%	-24.1%	-6.3%	-6.9%	-14.4%
May 29	BofA Securities	Maintains	Neutral → Neutral	—	$3.71	$3.70	-0.3%	+6.7%	+13.2%	-6.2%	-18.3%	-13.5%
Jan 2	BofA Securities	Downgrade	Buy → Neutral	—	$1.78	$1.74	-2.2%	-3.9%	-15.7%	-15.2%	-18.0%	-16.9%
Dec 21	Jefferies	Maintains	Buy → Buy	—	$7.30	$7.45	+2.0%	+3.2%	+1.6%	-10.5%	-15.8%	-25.1%
Nov 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$10.55	$10.65	+0.9%	+0.9%	+7.9%	+6.2%	+2.7%	-0.9%
Oct 18	UBS	Maintains	Buy → Buy	—	$9.97	$10.30	+3.3%	+0.0%	+1.8%	+3.6%	+3.0%	+1.0%
Oct 14	Citigroup	Maintains	Buy → Buy	—	$10.25	$10.50	+2.4%	-3.3%	-2.7%	-2.7%	-1.0%	+0.8%
Sep 2	Evercore ISI	Maintains	Outperform → Outperform	—	$9.67	$10.00	+3.4%	+5.5%	-27.6%	-19.3%	-15.5%	+1.8%

Data updated apr 26, 2026 8:47pm · Source: massive.com